Morepen Laboratories reported its highest-ever quarterly performance in Q1 FY27, with revenue rising 34% YoY to ₹575.31 crore and PAT surging 394% to ₹56.35 crore. The company also began commercial execution of its ₹825 crore CDMO mandate, while API exports jumped 42%, driving the stock to hit the 20% upper circuit.